Literature DB >> 9005985

Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody.

H Heath1, S Qin, P Rao, L Wu, G LaRosa, N Kassam, P D Ponath, C R Mackay.   

Abstract

Chemokines bind and signal through G-protein coupled seven transmembrane receptors. Various chemokine receptors are expressed on leukocytes, and these may impart selective homing of leukocyte subsets to sites of inflammation. Human eosinophils express the eotaxin receptor, CCR3, but respond to a variety of CC chemokines apart from eotaxin, including RANTES, monocyte chemotactic protein (MCP)-2, MCP-3, and MCP-4. Here we describe a mAb, 7B11, that is selective for CCR3 and has the properties of a true receptor antagonist. 7B11 blocked binding of various radiolabeled chemokines to either CCR3 transfectants, or eosinophils. Pretreatment of eosinophils with this mAb blocked chemotaxis and calcium flux induced by all CCR3 ligands. In all individuals examined, including allergic and eosinophilic donors, > 95% of the response of eosinophils to eotaxin, RANTES, MCP-2, MCP-3, and MCP-4 was shown to be mediated through CCR3. The IL-8 receptors, particularly CXCR2, were induced on IL-5 primed eosinophils, however these eosinophils responded to CC chemokines in the same manner as unprimed eosinophils. These results demonstrate the importance of CCR3 for eosinophil responses, and the feasibility of completely antagonizing this receptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9005985      PMCID: PMC507784          DOI: 10.1172/JCI119145

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

Review 1.  CC chemokines in allergic inflammation.

Authors:  M Baggiolini; C A Dahinden
Journal:  Immunol Today       Date:  1994-03

Review 2.  Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines.

Authors:  M Baggiolini; B Dewald; B Moser
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

3.  Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails.

Authors:  I F Charo; S J Myers; A Herman; C Franci; A J Connolly; S R Coughlin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

4.  Chemokine receptors and T cell chemotaxis.

Authors:  C R Mackay
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

5.  Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant.

Authors:  M W Carr; S J Roth; E Luther; S S Rose; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

6.  Neutralizing monoclonal antibodies to human IL-8 receptor A map to the NH2-terminal region of the receptor.

Authors:  A Chuntharapai; J Lee; J Burnier; W I Wood; C Hébert; K J Kim
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

7.  CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines.

Authors:  A Hartnell; D S Robinson; A B Kay; A J Wardlaw
Journal:  Immunology       Date:  1993-10       Impact factor: 7.397

8.  Biochemical and biologic characterization of murine monocyte chemoattractant protein-1. Identification of two functional domains.

Authors:  C A Ernst; Y J Zhang; P R Hancock; B J Rutledge; C L Corless; B J Rollins
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

9.  Alpha 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep.

Authors:  W M Abraham; M W Sielczak; A Ahmed; A Cortes; I T Lauredo; J Kim; B Pepinsky; C D Benjamin; D R Leone; R R Lobb
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

10.  Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation.

Authors:  P J Jose; D A Griffiths-Johnson; P D Collins; D T Walsh; R Moqbel; N F Totty; O Truong; J J Hsuan; T J Williams
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

View more
  88 in total

Review 1.  Chemokines and asthma: redundancy of function or a coordinated effort?

Authors:  N W Lukacs; S H Oliveira; C M Hogaboam
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

Review 2.  Immune chemokines and their receptors: the key elements in the genesis, homeostasis and function of the immune system.

Authors:  O Yoshie
Journal:  Springer Semin Immunopathol       Date:  2000

Review 3.  Genes that regulate eosinophilic inflammation.

Authors:  D H Broide; H Hoffman; P Sriramarao
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

Review 4.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 5.  Science, medicine, and the future. Allergic disorders.

Authors:  S T Holgate
Journal:  BMJ       Date:  2000-01-22

Review 6.  Eotaxin and asthma: some answers, more questions.

Authors:  C J Corrigan
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

Review 7.  Chemokines in allergic lung inflammation.

Authors:  Clare Lloyd
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

8.  Protective effect of eotaxin-2 inhibition in adjuvant-induced arthritis.

Authors:  J N Ablin; M Entin-Meer; V Aloush; S Oren; O Elkayam; J George; I Barshack
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

9.  High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines.

Authors:  M Uguccioni; C R Mackay; B Ochensberger; P Loetscher; S Rhis; G J LaRosa; P Rao; P D Ponath; M Baggiolini; C A Dahinden
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

10.  Chemokines in the limbal form of vernal keratoconjunctivitis.

Authors:  A M Abu El-Asrar; S Struyf; S A Al-Kharashi; L Missotten; J Van Damme; K Geboes
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.